

## Surface Plasmon Resonance Analysis of Antigen-Antibody Interaction

Mitsuhiro Nishimura and Kazuyoshi Ikuta\*

Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

\*For correspondence: [ikuta@biken.osaka-u.ac.jp](mailto:ikuta@biken.osaka-u.ac.jp)

**[Abstract]** Molecular interaction between monoclonal antibodies (MAbs) and their recognized antigen is a fundamental event leading to the neutralization activity. Estimation of their binding affinity gives beneficial information to characterize the MAbs and to develop more effective MAbs. Surface plasmon resonance (SPR) analysis is a powerful tool to analyze the molecular interaction, enabling rapid and repetitive estimation with relatively small amount of sample. Here we describe a general protocol about SPR analysis on the interaction between viral antigen and human MAb (HuMAb) IgG. Anti-human Fc $\gamma$  is first covalently crosslinked on the sensor chip by amine coupling, and then HuMAb of interest is immobilized via anti-Fc $\gamma$  MAb IgG interaction as ligand. Antigen injected on the sensor chip causes the SPR change in time course as the result of association and dissociation. By analyzing the kinetics, association rate, dissociation rate, and dissociation constant are obtained.

### **Materials and Reagents**

1. Purified HuMAb (IgG)
2. Purified antigen
3. 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) (Nacalai tesque, catalog number: 17514-15)
4. Sodium hydroxide (Wako Pure Chemical Industries, catalog number: 198-13765)
5. 2 mol/L sodium hydroxide solution (Nacalai Tesque, catalog number: 37441-45)
6. Sodium acetate, anhydrous (Wako Pure Chemical Industries, catalog number: 192-01075)
7. Ethylenediamine-N,N,N',N'-tetraacetic acid, disodium salt, dihydrate (EDTA·2Na) (Dojindo Molecular Technologies, catalog number: 345-01865)
8. Polyoxyethylene(20) sorbitan monolaurate (Wako Pure Chemical Industries, catalog number: 167-11515)
9. Goat Anti-Human Fc $\gamma$  (Jackson ImmunoResearch Laboratories INC., catalog number: 109-005-008)
10. 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) (Thermo Fisher Scientific, catalog number: 22980)

11. *N*-hydroxysulfosuccinimide (NHS) (Thermo Fisher Scientific, catalog number: 24500)
12. Acetic acid (Wako Pure Chemical Industries, catalog number: 017-00256 )
13. 2-ethanolamine (Nacalai tesque, catalog number: 23405-42)
14. Hydrochloric acid (Wako Pure Chemical Industries, catalog number: 080-01066)
15. Magnesium chloride hexahydrate (Wako Pure Chemical Industries, catalog number: 135-00165)
16. Sodium Chloride (Nacalai tesque, catalog number: 321319-45)
17. Glycine (Nacalai tesque, catalog number: 17109-35)
18. EDC/NHS solution
19. 0.5 M HEPES buffer (pH 7.4) (see Recipes)
20. 0.5 M EDTA (pH 8.0) (see Recipes)
21. 20% (v/v) polysorbate 20 (see Recipes)
22. 10x HBS-E (see Recipes)
23. 1x HBS-EP (see Recipes)
24. 400 mM EDC (see Recipes)
25. 100 mM NHS (see Recipes)
26. 1 M 2-ethanolamine (pH 8.5) (see Recipes)
27. 50 mM NaOH (see Recipes)
28. 10 mM Acetate buffer (pH 4.0, 4.5, 5.0, 5.5) (see Recipes)
29. Glycine buffer 10 mM (pH 1.8, 2.0 2.2, 2.4) (see Recipes)
30. 1 M NaCl (see Recipes)
31. 3 M MgCl<sub>2</sub> (see Recipes)

## Equipment

1. Instrument for SPR analysis, e.g. Biacore T200 (GE) or ProteOn XPR36 (Bio-Rad Laboratories)
2. Sensor chip (with carboxyl groups available for the amine coupling reaction), e.g. Series S Sensor Chip CM5 (GE, catalog number: BR-1005-30) for Biacore T200 or ProteOn GLM Sensor Chip (Bio-Rad Laboratories, catalog number: 176-5012) for ProteOn XPR36.
3. Vacuum pump
4. 0.22 µm PES PLUS bottom top filter (IWAKI PUMPS, catalog number: 8024-045)
5. 0.22 µm Millex-GV syringe filter unit (Millipore, catalog number: SLGV033RS)
6. 20 ml syringe (Thermo Fisher Scientific, catalog number: SS-20ESZ)
7. Centrifuge
8. 1.5 ml centrifuge tube (Ina-optika corporation, catalog number: CF-0150)
9. Spectra/Por 3 Dialysis trial kit (SPECTRUM® LABORATORIES, catalog number: 132720T)

10. Stir bar and stirrer
11. UV spectrometer
12. pH meter

## **Procedure**

### **A. Preparation of reagents and sample**

1. Prepare reagents (HBS-EP buffer, 400 mM EDC, 100 mM NHS, 50 mM NaOH, 1 M 2-ethanolamine-HCl, glycine buffers and acetate buffers).

Wash dialysis membrane by 300 ml of dH<sub>2</sub>O and dialyze antigen in 1 L of HBS-EP buffer on stirrer at 4 °C for at least 8 h. The HBS-EP buffer should be changed to fresh one twice with at least 8 h interval.

*Notes:*

- a. *Imbalance in the refractive index between antigen solution and running buffer will cause high background signal (called bulk effect) and perturb the SPR analysis.*
- b. *The concentration of antigen is recommended to be 5 μM or higher, because the dissociation constant for weak antigen-antibody interaction sometimes reaches to 10<sup>-6</sup> M range and in that case SPR experiment requires relatively high concentration of antigen, that is 5 μM or more.*

2. Determine antigen concentration by ultraviolet UV spectroscopy or standard BCA analysis.

### **B. Immobilization of anti-human Fcγ on sensor chip**

1. Set sensor chip into the SPR instrument.

*Note: In all steps dealing with the instrument, you should follow the instrument's manual.*

2. Set the 1 L of HBS-EP buffer as running buffer.
3. Prepare 300 μl l of ligand solutions: 100 μg/ml anti-human Fcγ solutions of four different pH values (4.0, 4.5, 5.0 and 5.5) by diluting with the 10 mM acetate buffer.
4. Inject ligand solutions and determine the optimum pH condition in which the highest response level is observed (Figure 1a).

*Note: When there is little or no difference, select higher pH in order to avoid ligand deterioration and to promote coupling reaction. Practically, pH 4.0 or 4.5 is selected for immobilization of anti-human Fcγ, though you should determine for your SPR system.*

5. Initialize the chip surface by injecting 30 μl of 50 mM NaOH.
6. Activate the chip surface by injecting 70 μl of 1:1 EDC/NHS mix.
7. Inject anti-human Fcγ solution and check the baseline increment. Repeat injection until the increment becomes undetectable.

*Note: In this step anti-human Fc $\gamma$  should immobilize as much as possible. Usually, approx. 8,000 (Resonance Unit, RU) increment is obtained.*

8. Inject 70  $\mu$ l of 1 M 2-ethanolamine-HCl solution to block the active carboxyl groups remained on the sensor chip.

*Note: If you want stop the experiment in this step, eject the sensor chip from the instrument and store at 4 °C in HBS-EP buffer to prevent drying out.*

#### C. Check the antigen-MAb interaction and design experiment.

1. Prepare 1 ml of 1  $\mu$ g/ml MAb solution by diluting with HBS-EP buffer.

*Note: The original MAb solution should not include any reagents which perturb the interaction between MAb and anti-human Fc $\gamma$ , for example, 100 mM glycine buffer of pH 2.4 or lower.*

2. Inject target MAb and check the immobilization amount as the increment of baseline level.

*Note: For SPR analysis, smaller immobilization amount is preferred as far as the response against antigen gives sufficient signal.*

3. Inject 30  $\mu$ l of 10 mM glycine solutions of different pH values 1.8, 2.0, 2.2, and 2.4. By checking the decrement of the baseline level, determine the MAb-stripping condition (pH, injection period, number of injections, period required for baseline stabilization).

*Note: The baseline level should be close to the level before MAb immobilization. An example of practical condition is as follows: Inject 30  $\mu$ l of 10 mM Glycine pH 2.0 thrice and wash by running buffer for 600 seconds as baseline stabilization period.*

4. Prepare 1 ml of 1  $\mu$ M antigen solution by diluting with HBS-EP buffer.

5. Clarify the antigen solution by centrifugation at 15,000  $\times g$  for 5 min at room temperature.

6. Inject 60  $\mu$ l of the antigen solution and check the SPR response.

*Note: The minimum response level is 1 RU or less as far as the response curve is recognizable, though it apparently depends on the baseline stability, in other words, stability of the SPR system.*

7. Determine antigen-stripping condition by injecting 60  $\mu$ l of 1 M NaCl or 3 M MgCl<sub>2</sub>.

*Note: As other option, you can remove the whole antigen-MAb with glycine buffer and retry from the MAb immobilization step. Antigen-stripping condition is not necessarily required depending on the experimental design.*

8. Prepare 1 ml of antigen solutions of at least 5 different concentrations by 1:1 serial dilution with HBS-EP buffer.

9. Determine the experimental design considering the following points.

- a. MAb immobilization condition.

- b. Injection period for the antigen solution and washing period.

*Notes:*


- i. They are corresponding to the lengths of association and dissociation phases, respectively. Set appropriate values to obtain significant signal level and sufficient curvature.
- ii. In some cases antigen dissociates very slowly from MAb, and then we need to set very long washing period. When no dissociation is observed, try reducing the immobilizing level of MAb.
- c. Antigen-stripping condition.
- d. Design of blank experiment: without MAb immobilization and/or injecting HBS-EP buffer in replace of antigen solution.
- e. Setting for individual flow paths.

*Note: Usually, SPR system has multiple flow paths useful for blank experiment and for examination of multiple MAbs at once.*

#### D. Curve analysis

1. Collected experimental data is analyzed according to the fitting algorithm supplied by vendor of the SPR system (For example, see Figure 1c). Usually, 1:1 Langmuir fitting model is employed.

*Note: Check the chi-square value and quality index supplied by the software.*



**Figure 1. Practical example of the SPR experiment**

- a. Determination of the pH value for amine-coupling immobilization of anti-human Fc $\gamma$ . pH 4.0 showed the highest response, however, it also showed signs of leveling off. Then, we have chosen pH 4.5 in this case. Open arrowhead and closed arrowhead indicate the start and end points of the injection of anti-human Fc $\gamma$  solution, respectively.
- b. Immobilization of MAb on the sensor chip via the interaction between anti-human Fc $\gamma$  and human MAb. Open arrowhead and closed arrowhead indicate the start and end points of the injection of human MAb solution, respectively. The increment of baseline level (in this case, approx. 10 RU) represents the immobilized amount of MAb.
- c. Representative SPR response for the interaction between influenza B hemagglutinin

(HA) and a human anti-HA antibody. Open arrowheads indicate the injection of HA solution and correspond to the association phase. Closed arrowhead indicates the end of the final injection and corresponds to the start of the dissociation phase. Fitting curve obtained by the 1:1 Langmuir fitting model was also shown by gray line.

## **Notes**

1. Usually SPR analysis is performed under an integrated system in which equipment (sensor chip, buffer bottle, sample tube, etc), experimental design, analysis algorithm and even in reagents are all supplied for using that instrument. We just described here a general procedure of SPR experiment for antigen-MAb interaction analysis. Please follow the manual of your instrument and/or contact the vendor for more detailed protocol.

## **Recipes**

1. 0.5 M HEPES buffer (pH 7.4) (500 ml)

Mix 59.6 g of HEPES powder with 400 ml dH<sub>2</sub>O

Adjust pH to 7.4 with NaOH

Add dH<sub>2</sub>O to 500 ml

Filtrate by 0.22 µm bottom top filter and vacuum pump

2. 0.5 M EDTA (pH 8.0) (500 ml)

Mix 93.1 g of EDTA·2Na with 400 ml dH<sub>2</sub>O

Adjust pH to 8.0 with NaOH

Add dH<sub>2</sub>O to 500 ml

Filtrate by 0.22 µm bottom top filter and store at room temperature

3. 20 % (v/v) polysorbate 20 (500 ml)

Add 400 ml dH<sub>2</sub>O to 100 ml polyoxyethylene(20) sorbitan monolaurate

4. 10x HBS-E (500 ml)

Mix 100 ml 0.5 M HEPES buffer, pH 7.4

30 ml 0.5 M EDTA, pH 8.0

44 g NaCl

Add dH<sub>2</sub>O to 500 ml

5. 1x HBS-EP (4 L)

10x HBS-E buffer 400 ml

Add dH<sub>2</sub>O to 4 L

Filtrate by 0.22 µm bottom top filter and vacuum pump

Add 1 ml 20% (v/v) polysorbate 20

6. 400 mM EDC (10 ml)  
Dissolve 750 mg EDC in 10 ml dH<sub>2</sub>O  
Dispense 200  $\mu$ l into 1.5 ml tubes and store at -20 °C
7. 100 mM NHS (10 ml)  
Dissolve 115 mg NHS in 10 ml dH<sub>2</sub>O  
Dispense 200  $\mu$ l into 1.5 ml tubes and store at -20 °C
8. 1 M 2-ethanolamine (pH 8.5) (50 ml)  
Dilute 3.0 ml of 2-ethanolamine with dH<sub>2</sub>O to 40 ml  
Adjust pH to 8.5 by HCl  
Add dH<sub>2</sub>O to 50 ml  
Dispense 1 ml into 1.5 ml tubes and store at 4 °C
9. 50 mM NaOH (10 ml)  
Dilute 250  $\mu$ l of 2 M NaOH solution with dH<sub>2</sub>O to 10 ml  
Dispense 1 ml into 1.5 ml tubes and store at room temperature
10. 10 mM Acetate buffer (pH 4.0, 4.5, 5.0, 5.5) (50 ml each)  
Mix 8.2 g sodium acetate with 100 ml dH<sub>2</sub>O to prepare 1 M acetate-Na  
Dilute 5.7 ml of acetate with 100 ml dH<sub>2</sub>O to prepare 1 M acetate  
Prepare 10 mM acetate-Na and 10 mM acetate by 100-fold dilution with dH<sub>2</sub>O  
Adjust pH by mixing 10 mM acetate and 10 mM acetate-Na  
Filtrate by 0.22  $\mu$ m filter and syringe
11. Glycine buffer 10 mM (pH 1.8, 2.0 2.2, 2.4) (50 ml each)  
Mix 0.30 g glycine with dH<sub>2</sub>O and add dH<sub>2</sub>O to 200 ml  
Dispense 50 ml glycine solution into 100 ml beaker  
Adjust pH by adding HCl  
Add dH<sub>2</sub>O to 100 ml  
Filtrate by 0.22  $\mu$ m filter and syringe
12. 1 M NaCl  
Mix 2.9 g NaCl with dH<sub>2</sub>O to 50 ml  
Filtrate by 0.22  $\mu$ m filter and syringe
13. 3 M MgCl<sub>2</sub>  
Mix 30.5 g MgCl<sub>2</sub>·6H<sub>2</sub>O with dH<sub>2</sub>O and adjust volume to 50 ml  
Filtrate by 0.22  $\mu$ m filter and syringe

### Acknowledgments

This protocol was established by reference to the product manuals of Biacore T200 (GE-Healthcare) and ProteOn XPR36 (BIO-RAD).

## **References**

1. Yasugi, M., Kubota-Koketsu, R., Yamashita, A., Kawashita, N., Du, A., Sasaki, T., Nishimura, M., Misaki, R., Kuhara, M., Boonsathorn, N., Fujiyama, K., Okuno, Y., Nakaya, T. and Ikuta, K. (2013). [Human monoclonal antibodies broadly neutralizing against influenza B virus](#). *PLoS Pathog* 9(2): e1003150.